Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Dec 2013

Domingo Enric, Church David N, Sieber Oliver, Ramamoorthy Rajarajan, Yanagisawa Yoko, Johnstone Elaine, Davidson Brian, Kerr David J, Tomlinson Ian P M, Midgley Rachel

Abstract excerpt

PURPOSE: Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) protect against colorectal cancer (CRC) and are associated with reduced disease recurrence and improved outcome after primary treatment. However, toxicities of NSAIDs have limited their use as antineoplastic therapy. Recent data have suggested that the benefit of aspirin after CRC diagnosis is limited to patients with PIK3CA-mutant cancers....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Inflammatory Agents, Non-Steroidal
Share to Aspirin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemotherapy, Adjuvant

Share to Colectomy

Share to Cyclooxygenase 2

Share to Lactones

Share to Patient Selection

Share to Sulfones

Source

Identifiers

PMID: 24062397
DOI: 10.1200/JCO.2013.50.0322

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.PMID 24062397Read ↗

Adjuvant aspirin and Cyclooxygenase-2 inhibitors in resected, PIK3CA-mutated colorectal cancer: A systematic review and meta-analysis of randomized controlled trials.Semantic proximity Read ↗

Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation.Semantic proximity Read ↗

Adjuvant aspirin for colorectal cancer with PIK3CA-mutated and COX-2 overexpressed tumours: the ASCOLT translational research study and meta-analysis.Semantic proximity Read ↗

Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.Semantic proximity Read ↗

PIK3CA Mutation, Aspirin Use after Diagnosis and Survival of Colorectal Cancer. A Systematic Review and Meta-analysis of Epidemiological Studies.Semantic proximity Read ↗

Examining the impact of regular aspirin use and PIK3CA mutations on survival in stage 2 colon cancer.Semantic proximity Read ↗

Potential biomarker for aspirin use in colorectal cancer therapy.Semantic proximity Read ↗

Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance).Semantic proximity Read ↗

Aspirin therapy for colorectal cancer with PIK3CA mutation: simply complex!Semantic proximity Read ↗

The Association Between Colorectal Cancer and Pharmaceuticals with Emphasis on Low-Dose Aspirin and AnticoagulantsSemantic proximity Read ↗

Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer.Semantic proximity Read ↗

Can Cost-effectiveness Analysis Inform Genotype-Guided Aspirin Use for Primary Colorectal Cancer Prevention?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.